Quality Regulation and Competition: Evidence from Pharmaceutical Markets
Author
Abstract
Suggested Citation
Download full text from publisher
Other versions of this item:
- Atal, Juan Pablo & Cuesta, Jose Ignacio & Sæthre, Morten, 2018. "Quality Regulation and Competition: Evidence from Pharmaceutical Markets," Research Department working papers 1211, CAF Development Bank Of Latinamerica.
- Juan Pablo Atal & José Ignacio Cuesta & Morten Sæthre, 2022. "Quality Regulation and Competition: Evidence from Pharmaceutical Markets," NBER Working Papers 30325, National Bureau of Economic Research, Inc.
- Atal, Juan Pablo & Cuesta, José Ignacio & Sæthre, Morten, 2018. "Quality Regulation and Competition: Evidence from Pharmaceutical Markets," Discussion Paper Series in Economics 20/2018, Norwegian School of Economics, Department of Economics.
References listed on IDEAS
- Bart J. Bronnenberg & Jean-Pierre Dubé & Matthew Gentzkow & Jesse M. Shapiro, 2015.
"Do Pharmacists Buy Bayer? Informed Shoppers and the Brand Premium,"
The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 130(4), pages 1669-1726.
- Bart J. Bronnenberg & Jean-Pierre Dubé & Matthew Gentzkow & Jesse M. Shapiro, 2014. "Do Pharmacists Buy Bayer? Informed Shoppers and the Brand Premium," NBER Working Papers 20295, National Bureau of Economic Research, Inc.
- Mark Duggan & Craig Garthwaite & Aparajita Goyal, 2016.
"The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India,"
American Economic Review, American Economic Association, vol. 106(1), pages 99-135, January.
- Mark Duggan & Craig Garthwaite & Aparajita Goyal, 2014. "The Market Impacts Of Pharmaceutical Product Patents In Developing Countries: Evidence From India," Discussion Papers 14-005, Stanford Institute for Economic Policy Research.
- Mark Duggan & Craig Garthwaite & Aparajita Goyal, 2014. "The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India," NBER Working Papers 20548, National Bureau of Economic Research, Inc.
- Pierre Dubois & Morten Sæthre, 2020.
"On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector,"
Econometrica, Econometric Society, vol. 88(6), pages 2503-2545, November.
- Dubois, Pierre & Sæthre, Morten, 2017. "On the Effect of Parallel Trade on Manufacturers’ and Retailers’ Profits in the Pharmaceutical Sector," Discussion Paper Series in Economics 3/2018, Norwegian School of Economics, Department of Economics.
- Pierre Dubois & Morten Sæthre, 2020. "On the Effect of Parallel Trade on Manufacturers’ and Retailers’ Profits in the Pharmaceutical Sector," Post-Print hal-03176406, HAL.
- Dubois, Pierre & Saethre, Morten, 2018. "On the Effect of Parallel Trade on Manufacturers’ and Retailers’ Profits in the Pharmaceutical Sector," TSE Working Papers 18-883, Toulouse School of Economics (TSE), revised Mar 2020.
- Dubois, Pierre & Saethre, Morten, 2018. "On the Effect of Parallel Trade on Manufacturers' and Retailers' Profits in the Pharmaceutical Sector," CEPR Discussion Papers 12649, C.E.P.R. Discussion Papers.
- Scarpa, Carlo, 1998. "Minimum quality standards with more than two firms1," International Journal of Industrial Organization, Elsevier, vol. 16(5), pages 665-676, September.
- Richard G. Frank & David S. Salkever, 1997.
"Generic Entry and the Pricing of Pharmaceuticals,"
Journal of Economics & Management Strategy, Wiley Blackwell, vol. 6(1), pages 75-90, March.
- Richard G. Frank & David S. Salkever, 1995. "Generic Entry and the Pricing of Pharmaceuticals," NBER Working Papers 5306, National Bureau of Economic Research, Inc.
- Crampes, Claude & Hollander, Abraham, 1995.
"Duopoly and quality standards,"
European Economic Review, Elsevier, vol. 39(1), pages 71-82, January.
- Crampes, C. & Hollander, A., 1991. "Duopoly and Quality Standards," Cahiers de recherche 9128, Universite de Montreal, Departement de sciences economiques.
- Crampes, C. & Hollander, A., 1991. "Duopoly and Quality Standards," Cahiers de recherche 9128, Centre interuniversitaire de recherche en économie quantitative, CIREQ.
- Crampes, C. & Hollander, A., 1992. "Duopoly and Quality Standards," Papers 92.g, Toulouse - GREMAQ.
- Dubois, Pierre & Lasio, Laura, 2014.
"Identifying Industry Margins with Unobserved Price Constraints: Structural Estimation on Pharmaceuticals,"
IDEI Working Papers
823, Institut d'Économie Industrielle (IDEI), Toulouse.
- Dubois, Pierre & Lasio, Laura, 2014. "Identifying Industry Margins with Unobserved Price Constraints: Structural Estimation on Pharmaceuticals," CEPR Discussion Papers 9881, C.E.P.R. Discussion Papers.
- Dubois, Pierre & Lasio, Laura, 2014. "Identifying Industry Margins with Unobserved Price Constraints: Structural Estimation on Pharmaceuticals," TSE Working Papers 14-471, Toulouse School of Economics (TSE), revised Mar 2018.
- Paolo Garella & Emmanuel Petrakis, 2008.
"Minimum quality standards and consumers’ information,"
Economic Theory, Springer;Society for the Advancement of Economic Theory (SAET), vol. 36(2), pages 283-302, August.
- P. Garella & P. Petrakis, 2004. "Minimum Quality Standards and Consumers Information," Working Papers 532, Dipartimento Scienze Economiche, Universita' di Bologna.
- Paolo G. GARELLA & Emmanuel PETRAKIS, 2007. "Minimum quality standards and consumers’ information," Departmental Working Papers 2007-12, Department of Economics, Management and Quantitative Methods at Università degli Studi di Milano.
- Paolo Garella & Emmanuel Petrakis, 2005. "Minimum Quality Standards and Consumers Information," Working Papers 0510, University of Crete, Department of Economics.
- Fiona M. Scott Morton, 1999. "Entry Decisions in the Generic Pharmaceutical Industry," RAND Journal of Economics, The RAND Corporation, vol. 30(3), pages 421-440, Autumn.
- Avner Shaked & John Sutton, 1982. "Relaxing Price Competition Through Product Differentiation," The Review of Economic Studies, Review of Economic Studies Ltd, vol. 49(1), pages 3-13.
- Fiona M. Scott Morton, 1999. "Entry Decisions in the Generic Pharmaceutical Industry," Yale School of Management Working Papers ysm119, Yale School of Management.
- Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2016.
"Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry,"
RAND Journal of Economics, RAND Corporation, vol. 47(4), pages 857-890, November.
- Lee G. Branstetter & Chirantan Chatterjee & Matthew Higgins, 2011. "Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry," NBER Working Papers 17188, National Bureau of Economic Research, Inc.
- Boyan Jovanovic, 1982. "Truthful Disclosure of Information," Bell Journal of Economics, The RAND Corporation, vol. 13(1), pages 36-44, Spring.
- Pierre Dubois & Laura Lasio, 2018. "Identifying Industry Margins with Price Constraints: Structural Estimation on Pharmaceuticals," American Economic Review, American Economic Association, vol. 108(12), pages 3685-3724, December.
- Ginger Zhe Jin & Phillip Leslie, 2003. "The Effect of Information on Product Quality: Evidence from Restaurant Hygiene Grade Cards," The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 118(2), pages 409-451.
- Atanu Saha & Henry Grabowski & Howard Birnbaum & Paul Greenberg & Oded Bizan, 2006. "Generic Competition in the US Pharmaceutical Industry," International Journal of the Economics of Business, Taylor & Francis Journals, vol. 13(1), pages 15-38.
- Patrick Kline & Neviana Petkova & Heidi Williams & Owen Zidar, 2019.
"Who Profits from Patents? Rent-Sharing at Innovative Firms,"
The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 134(3), pages 1343-1404.
- Kline, Patrick & Petkova, Neviana & Williams, Heidi & Zidar, Owen, 2017. "Who Profits from Patents? Rent-Sharing at Innovative Firms," Institute for Research on Labor and Employment, Working Paper Series qt6mr8598q, Institute of Industrial Relations, UC Berkeley.
- Patrick Kline & Neviana Petkova & Heidi Williams & Owen Zidar, 2018. "Who Profits from Patents? Rent-Sharing at Innovative Firms," NBER Working Papers 25245, National Bureau of Economic Research, Inc.
- Duarte, Fabian, 2012. "Price elasticity of expenditure across health care services," Journal of Health Economics, Elsevier, vol. 31(6), pages 824-841.
- David Dranove & Ginger Zhe Jin, 2010.
"Quality Disclosure and Certification: Theory and Practice,"
Journal of Economic Literature, American Economic Association, vol. 48(4), pages 935-963, December.
- David Dranove & Ginger Zhe Jin, 2010. "Quality Disclosure and Certification: Theory and Practice," NBER Working Papers 15644, National Bureau of Economic Research, Inc.
- Jaskold Gabszewicz, J. & Thisse, J. -F., 1979.
"Price competition, quality and income disparities,"
Journal of Economic Theory, Elsevier, vol. 20(3), pages 340-359, June.
- GABSZEWICZ, Jean J. & THISSE, Jacques-François, 1979. "Price competition, quality and income disparities," LIDAM Reprints CORE 370, Université catholique de Louvain, Center for Operations Research and Econometrics (CORE).
- Darius N. Lakdawalla, 2018. "Economics of the Pharmaceutical Industry," Journal of Economic Literature, American Economic Association, vol. 56(2), pages 397-449, June.
- Bresnahan, Timothy F & Reiss, Peter C, 1991.
"Entry and Competition in Concentrated Markets,"
Journal of Political Economy, University of Chicago Press, vol. 99(5), pages 977-1009, October.
- Bresnahan, T.F & Reiss, P.C., 1989. "Entry And Competition In Concentrated Markets," Papers 151, Stanford - Studies in Industry Economics.
- Neha Bairoliya & Pinar Karaca-Mandic & Jeffrey S. McCullough & Amil Petrin, 2017. "Consumer Learning and the Entry of Generic Pharmaceuticals," NBER Working Papers 23662, National Bureau of Economic Research, Inc.
- Uri Ronnen, 1991. "Minimum Quality Standards, Fixed Costs, and Competition," RAND Journal of Economics, The RAND Corporation, vol. 22(4), pages 490-504, Winter.
- Judith A. Chevalier & Anil K. Kashyap & Peter E. Rossi, 2003.
"Why Don't Prices Rise During Periods of Peak Demand? Evidence from Scanner Data,"
American Economic Review, American Economic Association, vol. 93(1), pages 15-37, March.
- Judith A. Chevalier & Anil K. Kashyap & Peter E. Rossi, 2000. "Why Don't Prices Rise During Periods of Peak Demand? Evidence from Scanner Data," NBER Working Papers 7981, National Bureau of Economic Research, Inc.
- Peter E. Rossi & Judith A. Chevalier & Anil K. Kashyap, 2002. "Why Don't Prices Rise During Periods of Peak Demand? Evidence from Scanner Data," Yale School of Management Working Papers ysm291, Yale School of Management.
- Danzon, Patricia M & Chao, Li-Wei, 2000. "Does Regulation Drive out Competition in Pharmaceutical Markets?," Journal of Law and Economics, University of Chicago Press, vol. 43(2), pages 311-357, October.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Juan Pablo Atal & José Ignacio Cuesta & Felipe González & Cristóbal Otero, 2024.
"The Economics of the Public Option: Evidence from Local Pharmaceutical Markets,"
American Economic Review, American Economic Association, vol. 114(3), pages 615-644, March.
- Juan Pablo Atal & Jose Ignacio Cuesta & Felipe Gonzalez & Cristobal Otero, 2021. "The Economics of the Public Option:Evidence from Local Pharmaceutical Markets," PIER Working Paper Archive 21-012, Penn Institute for Economic Research, Department of Economics, University of Pennsylvania.
- Juan Pablo Atal & Jose Ignacio Cuesta & Felipe Gonzalez & Cristobal Otero, 2023. "The Economics of the Public Option: Evidence from Local Pharmaceutical Markets," Working Papers 951, Queen Mary University of London, School of Economics and Finance.
- Juan Pablo Atala & José Ignacio Cuesta & Felipe González & Cristóbal Otero, 2021. "The Economics of the Public Option: Evidence from Local Pharmaceutical Markets," Documentos de Trabajo 561, Instituto de Economia. Pontificia Universidad Católica de Chile..
- Juan Pablo Atal & José Ignacio Cuesta & Felipe González & Cristóbal Otero, 2022. "The Economics of the Public Option: Evidence from Local Pharmaceutical Markets," NBER Working Papers 30779, National Bureau of Economic Research, Inc.
- Geng, Hao & Shi, Ce Matthew, 2024. "Health policy, price regulation, and innovation: Evidence from China’s vaccine industry," Journal of Development Economics, Elsevier, vol. 167(C).
- Chatterjee, Chirantan & Gupta, Samarth, 2024. "Public entry and private prices: New evidence from Indian pharmaceutical markets," Journal of Economic Behavior & Organization, Elsevier, vol. 219(C), pages 473-489.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Min Chen & Konstantinos Serfes, 2012. "Minimum quality standard regulation under imperfect quality observability," Journal of Regulatory Economics, Springer, vol. 41(2), pages 269-291, April.
- Olivier Bonroy & Christos Constantatos, 2015.
"On the Economics of Labels: How Their Introduction Affects the Functioning of Markets and the Welfare of All Participants,"
American Journal of Agricultural Economics, Agricultural and Applied Economics Association, vol. 97(1), pages 239-259.
- Bonroy, O. & Constantatos, C., 2014. "On the economics of labels : how their introduction affects the functioning of markets and the welfare of all participants," Working Papers 2014-03, Grenoble Applied Economics Laboratory (GAEL).
- Olivier Bonroy & Christos Constantatos, 2015. "On the economics of labels: how their introduction affects the functioning of markets and the welfare of all participants," Post-Print hal-01340827, HAL.
- Lee Branstetter & Chirantan Chatterjee & Matthew J. Higgins, 2016.
"Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry,"
RAND Journal of Economics, RAND Corporation, vol. 47(4), pages 857-890, November.
- Lee G. Branstetter & Chirantan Chatterjee & Matthew Higgins, 2011. "Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry," NBER Working Papers 17188, National Bureau of Economic Research, Inc.
- repec:gbl:wpaper:2013-01 is not listed on IDEAS
- Joan Costa-i-Font & Alistair McGuire & Nebibe Varol, 2011.
"Does Pharmaceutical Price Regulation Affect the Adoption of Generic Competition? Evidence from the OECD, 1999-2008,"
CESifo Working Paper Series
3441, CESifo.
- Costa-i-Font, Joan & Varol, Nebibe & McGuire, Alistair, 2011. "Does pharmaceutical price regulation affect the adoption of generic competition?: evidence from the OECD, 1999-2008," LSE Research Online Documents on Economics 37537, London School of Economics and Political Science, LSE Library.
- Garella, Paolo G. & Lambertini, Luca, 2014.
"Bidimensional vertical differentiation,"
International Journal of Industrial Organization, Elsevier, vol. 32(C), pages 1-10.
- Paolo Giorgio GARELLA & Luca LAMBERTINI, 2010. "Bidimensional vertical differentiation," Departmental Working Papers 2010-04, Department of Economics, Management and Quantitative Methods at Università degli Studi di Milano.
- Stefan Lutz & Mario Pezzino, 2012.
"International Strategic Choice of Minimum Quality Standards and Welfare,"
Journal of Common Market Studies, Wiley Blackwell, vol. 50(4), pages 594-613, July.
- Stefan Lutz & Mario Pezzino, 2009. "International Strategic Choice of Minimum Quality Standards and Welfare," ICER Working Papers 02-2009, ICER - International Centre for Economic Research.
- Iván Moreno-Torres & Jaume Puig-Junoy & Joan-Ramon Borrell, 2009. "Generic Entry into the Regulated Spanish Pharmaceutical Market," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 34(4), pages 373-388, June.
- Aljoscha Janssen, 2022. "Price dynamics of Swedish pharmaceuticals," Quantitative Marketing and Economics (QME), Springer, vol. 20(4), pages 313-351, December.
- Arcidiacono, Peter & Ellickson, Paul B. & Landry, Peter & Ridley, David B., 2013.
"Pharmaceutical followers,"
International Journal of Industrial Organization, Elsevier, vol. 31(5), pages 538-553.
- Peter Arcidiacono & Paul B. Ellickson & Peter Landry & David B. Ridley, 2013. "Pharmaceutical Followers," NBER Working Papers 19522, National Bureau of Economic Research, Inc.
- Clark, Robert & Fabiilli, Christopher & Lasio, Laura, 2022.
"Collusion in the US generic drug industry,"
International Journal of Industrial Organization, Elsevier, vol. 85(C).
- Robert Clark & Christopher Anthony Fabiilli & Laura Lasio, 2021. "Collusion in the US Generic Drug Industry," Working Paper 1474, Economics Department, Queen's University.
- Paolo Garella & Emmanuel Petrakis, 2008.
"Minimum quality standards and consumers’ information,"
Economic Theory, Springer;Society for the Advancement of Economic Theory (SAET), vol. 36(2), pages 283-302, August.
- P. Garella & P. Petrakis, 2004. "Minimum Quality Standards and Consumers Information," Working Papers 532, Dipartimento Scienze Economiche, Universita' di Bologna.
- Paolo G. GARELLA & Emmanuel PETRAKIS, 2007. "Minimum quality standards and consumers’ information," Departmental Working Papers 2007-12, Department of Economics, Management and Quantitative Methods at Università degli Studi di Milano.
- Paolo Garella & Emmanuel Petrakis, 2005. "Minimum Quality Standards and Consumers Information," Working Papers 0510, University of Crete, Department of Economics.
- Garella, Paolo G., 2006.
""Innocuous" minimum quality standards,"
Economics Letters, Elsevier, vol. 92(3), pages 368-374, September.
- Paolo Garella, 2006. ""Innocuous" Minimum Quality Standards," Working Papers 0606, University of Crete, Department of Economics.
- Lee, Chung-Ying, 2020. "Pricing strategy and moral hazard: Copay coupons in pharmaceuticals," International Journal of Industrial Organization, Elsevier, vol. 70(C).
- Stefan Napel & Gunnar Oldehaver, 2011.
"A dynamic perspective on minimum quality standards under Cournot competition,"
Journal of Regulatory Economics, Springer, vol. 39(1), pages 29-49, February.
- Stefan Napel & Gunnar Oldehaver, 2009. "A Dynamic Perspective on Minimum Quality Standards under Cournot Competition," Working Papers 082, Bavarian Graduate Program in Economics (BGPE).
- Patricia M. Danzon & Michael F. Furukawa, 2011. "Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets," NBER Working Papers 17226, National Bureau of Economic Research, Inc.
- Costa-Font, Joan & McGuire, Alistair & Varol, Nebibe, 2014. "Price regulation and relative delays in generic drug adoption," Journal of Health Economics, Elsevier, vol. 38(C), pages 1-9.
- Cédric Argenton, 2010.
"Exclusive Quality,"
Journal of Industrial Economics, Wiley Blackwell, vol. 58(3), pages 690-716, September.
- Argenton, Cédric, 2006. "Exclusive Quality," SSE/EFI Working Paper Series in Economics and Finance 640, Stockholm School of Economics, revised 05 Jun 2007.
- Argenton, C., 2008. "Exclusive Quality," Other publications TiSEM d5f5bf98-a17f-442e-ac09-e, Tilburg University, School of Economics and Management.
- Argenton, C., 2008. "Exclusive Quality," Discussion Paper 2008-20, Tilburg University, Center for Economic Research.
- Argenton, C., 2008. "Exclusive Quality," Discussion Paper 2008-007, Tilburg University, Tilburg Law and Economic Center.
- Argenton, C., 2008. "Exclusive Quality," Other publications TiSEM ee55b3e4-d0e9-4f2a-908b-3, Tilburg University, School of Economics and Management.
- Eric Giraud-Héraud & Cristina Grazia & Abdelhakim Hammoudi, 2012. "Explaining the Emergence of Private Standards in Food Supply Chains," Working Papers hal-00749345, HAL.
- Olivier Bonroy, 2006.
"Le standard de qualité minimale est-il un instrument socialement optimal ?. Une revue de littérature,"
Revue économique, Presses de Sciences-Po, vol. 57(1), pages 35-53.
- Bonroy, Olivier, 2003. "Le standard de qualité minimale est-il un instrument socialement optimal? Une revue de littérature," Cahiers de recherche 0304, GREEN.
- Olivier Bonroy, 2006. "Le standard de qualité minimale est-il un instrument socialement optimal? Une revue de littérature," Post-Print hal-01523757, HAL.
- Newham, M. & Seldeslachts, J. & Banal-Estanol, A., 2018.
"Common Ownership and Market Entry: Evidence from the Pharmaceutical Industry,"
Working Papers
18/03, Department of Economics, City University London.
- Melissa Newham & Jo Seldeslachts & Albert Banal-Estanol, 2018. "Common Ownership and Market Entry: Evidence from Pharmaceutical Industry," Discussion Papers of DIW Berlin 1738, DIW Berlin, German Institute for Economic Research.
- Albert Banal-Estañol & Melissa Newham & Jo Seldeslachts, 2018. "Common Ownership and Market Entry: Evidence from the Pharmaceutical Industry," Working Papers 1042, Barcelona School of Economics.
- Melissa Newham & Jo Seldeslachts & Albert Banal-Estanol, 2018. "Common ownership and market entry: Evidence from the pharmaceutical industry," Working Papers of Department of Management, Strategy and Innovation, Leuven 623896, KU Leuven, Faculty of Economics and Business (FEB), Department of Management, Strategy and Innovation, Leuven.
- Melisa Newham & Jo Seldeslachts & Albert Banal-Estañol, 2018. "Common ownership and market entry: Evidence from the pharmaceutical industry," Economics Working Papers 1612, Department of Economics and Business, Universitat Pompeu Fabra.
More about this item
Keywords
Aggregate quality regulation; competition; bioequivalence; generic pharmaceuticals;All these keywords.
JEL classification:
- I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
- L11 - Industrial Organization - - Market Structure, Firm Strategy, and Market Performance - - - Production, Pricing, and Market Structure; Size Distribution of Firms
- L15 - Industrial Organization - - Market Structure, Firm Strategy, and Market Performance - - - Information and Product Quality
NEP fields
This paper has been announced in the following NEP Reports:- NEP-COM-2019-09-30 (Industrial Competition)
- NEP-HEA-2019-09-30 (Health Economics)
- NEP-IND-2019-09-30 (Industrial Organization)
- NEP-LAM-2019-09-30 (Central and South America)
- NEP-REG-2019-09-30 (Regulation)
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:pen:papers:19-017. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Administrator (email available below). General contact details of provider: https://edirc.repec.org/data/deupaus.html .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.